The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13.

Salah Zangenah,Linda Björkhem-Bergman,Anna-Carin Norlin,Susanne Hansen,Lars Lindqvist,Birgitta Henriques-Normark,Peter Bergman

Vaccine（2017）

引用 2|浏览6

暂无评分

摘要

•IgG-deficient patients responded to Prevnar13 vaccination with lower Opa-titers than controls.•An almost normal vaccine response to pneumococcal serotypes 6A and 6B was recorded.•Most IgG-deficient patients reached Opa-titers of ≥8 and anti-pneumococcal IgG levels of 0.35µg/ml by 4weeks post vaccination.•Prevnar13 could confer a clinical benefit for IgG1- and IgG2-deficient patients.

查看译文

关键词

Pneumococcal vaccines,Pneumonia,IgG1-deficiency,IgG2-deficiency,Opsonophagocytic IgG,Pneumococcal infection,Clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要